Blood Glucose Test Strip Market Outlook, Size, Share & Key Companies by 2032

Market Scenario

The blood glucose test strip market share is presumed to garner USD 37.51 Billion during the forecast period (2023-2032). The market is presumed to register 7.2 % CAGR owing to the increasing diabetic population, asserts Market Research Future (MRFR). Blood glucose test strip can be referred to as a small non-reusable plastic strip. It is a crucial component of blood glucose meters that helps to monitor and control diabetes.

Competitive Dashboard

The blood glucose test strip market players operating the global market are

·        Apex Biotechnology Corp,

·        Shanghai

·        MicroSense,

·        ALL Medicus,

·        Beijing Yicheng Electronics,

·        Elektronika,

·        Nipro Diagnostics,

·        Bayer Diabetes Care,

·        B. Braun, LifeScan,

·        ACON Laboratories,

·        Jiangsu Yuyue,

·        HMD BioMedical Inc.,

·        TaiDoc,

·        Betachek National Diagnostics,

·        Roche Diagnostics,

·        i-SENS, Universal Biosensors,

·        Abbott,

·        SANNUO,

·        AgaMatrix Inc,

·        and others.

Regional Insights

Geographically, the global blood glucose test strip market insight span across regions namely, North America, Europe, Asia Pacific, and the Middle East and Africa.

Among all the regions, North America is presumed to lead the global blood glucose test strip market with $ 7.89 billion revenue. The growth is attributed to the extensive use of information technology coupled with high expenditure on healthcare. Moreover, the presence of major medical device manufacturers and high adoption of latest technologies are considered to stimulate the market during the review period.

Europe is estimated to hold the second position in the global market and is likely to maintain its dominance during the review period. High healthcare expenditure led by France and Germany is anticipated to drive the global market.

The Asia Pacific region is presumed to expand at a rapid pace owing to the presence of major regions such as India and China which are expected to lead the market due to unmet needs. This region is presumed to expand at 12.9 % CAGR owing to the growing number of diabetic population.

Drivers and Constraints Impacting the Market

Blood glucose test strips are self-testing strips which let pre-diabetic and diabetic people track their blood glucose level on a regular basis without visiting a diagnostic laboratory or a clinic. With the growing diabetic population, the global market for blood glucose test strip is considered to foster during the assessment period. For instance, as per the International Diabetic Federation, around 415 million people had diabetes in 2015. The number is estimated to reach 642 million by the end of 2040. Moreover, technological advancements such as accuracy of the tests along with awareness among the people regarding diabetes are stimulating market growth.

On the flip side, product recall owing to the inefficiency of devices such as intense competition resulting in pricing pressure and false glucose reading are some of the major factors considered to impede the global blood glucose test strip market in the coming years.

Global Blood Glucose Test Strip Market: Segmental Analysis

The blood glucose test strip market has been segmented on the basis of technology, distribution channel, and region.

By mode of technology, the global blood glucose test strip market has been segmented into optical, thin film electrochemical, and thick film electrochemical.

By mode of distribution channel, the blood glucose test strip market outlook has been segmented into retail pharmacy and hospital pharmacy. Among these, the hospital pharmacy is likely to dominate the global market and is anticipated to maintain its dominance over the assessment period. The growth is attributed to the increasing preference for self-care testing among the patients to monitor diabetes.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Healthcare Fraud Detection Market Outlook & Regional Analysis 2032

Market Analysis

The global healthcare fraud detection market share is projected to reach at CAGR 29.5% during the forecast year 2023-2032. Healthcare fraud takes places when a healthcare provider or an insured person offers misleading or false information to health insurance companies with an intention to have it paid to another party, individual, healthcare provider or policy holder for unauthorized benefits. Health care fraud comprise of medical fraud, drug fraud and health insurance fraud. Some common examples of such fraud include misrepresenting dates, duration, description of services and frequency, submitting claims for services that is not provided, numerous claims filed for same patients by different providers, data falsification by physicians. Healthcare fraud detection will help to prevent healthcare fraud, abuse and waste.

There are many factors that is driving the growth of the healthcare fraud detection market. Some of these factors as per the Market Research Future (MRFR) report include increasing fraudulent activities in the healthcare sector, growing number of patients looking for health insurance, prepayment review model, increasing pressure of abuse, waste and fraud on healthcare spending, high investment returns, and thorough and stringent checks in claims procedure to reduce losses to insurance companies. On the contrary, factors such as requirement for recurrent upgrades made in the fraud detection software, time-consuming deployment and the reluctance to use healthcare fraud analytics especially in the developing economies may impede the healthcare fraud detection market growth.

Market Segmentation

Market Research Future report offers an all-inclusive segmental analysis of the healthcare fraud detection market on the basis of component, end-user, delivery model, application and type.

Based on component, it is segmented into software and services. Of these, services will dominate the market over the estimated years.

Based on end-users, the healthcare fraud detection market outlook is segmented into private insurance payers, employers, government agencies and others.

Based on delivery model, it is segmented into on-premise and on-demand delivery models. Of these, on-demand will dominate the market.

Based on application, the healthcare fraud detection market is segmented into insurance claims review and payment integrity. The insurance claims review is again segmented into post and prepayment review. Of these, insurance claims review will dominate the market.

Based on type, it is segmented into prescriptive analytics, descriptive analytics and predictive analytics. Of these, descriptive analytics will lead the healthcare fraud detection market over the estimated years.

Key Players

healthcare fraud detection market players include Pondera Solutions, Northrop Grumman, DXC Technology, CGI Group, Scio Health Analytics, International Business Machines Corporation (IBM), LexisNexis, Wipro, Conduent, HCL Technologies, SAS Institute, Fair Isaac, McKesson, Verscend Technologies, Optum and others.  

Regional Analysis

Based on region, the healthcare fraud detection market insights covers growth opportunities and latest trends across Americas, Europe, Asia Pacific and Middle East and Africa. Of these, Americas will govern the market over the estimated years owing to increasing fraud cases in healthcare sector, promising government initiatives for preventing fraud in healthcare sector and more and more people requesting for health insurance. This will be followed by Europe that holds the second position owing to rising incidences of corruption and healthcare fraud in the region, developing state to cut down fraud within the healthcare sector and progress of the information technology sector. In the APAC region, the healthcare fraud detection market is predicted in being the fastest developing due to increasing frequency of frauds, evolving IT sector and constantly developing economies. On the other hand, the healthcare fraud detection market in the Middle East and Africa will have the least share. The Middle Eastern region however is anticipated to have a key share owing to the increasing health insurance frauds cases.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Smart Pills Market Outlook, Trends, Size and Forecast To 2032

Market summery

Market Research Future (MRFR's) study on the global smart pills market share is projected to grow USD 2.01 billion by 2032 at a CAGR of 15.9% over the forecast period of 2023-2032.

Amidst cut-throat competition, reimbursement issues, and expiry of blockbuster patent drugs, there is immense pressure on the healthcare sector to innovate diagnosis solutions. This has provided fuel for the advancement and commercialization of the smart pill technology which has been there for decades.

Smart pills are aligned with smart pills such as greater flexibility, precise delivery, real-time measurements, and monitoring of GI tract, and controlled operation or performance have acted as factors which can be employed to great advantage in drug development. They have several important applications, especially in diagnosis.

With the surge in the occurrence of chronic diseases, especially gastrointestinal diseases, smart pills are increasingly emerging as an effective method of endoscopy. Lifestyle diseases such as gastroesophageal reflux disease (GERD), obesity, and gastric ulcers are on the rise due to rapid lifestyle changes and unhealthy eating habits. This has induced high demand for on-site diagnosis, and, in turn, drive the market for smart pills. Surging prevalence of colon cancer is a key factor which is motivating the growth of the smart pills market.

Smart pills have been a breakthrough in gastrointestinal tract diagnosis and are set to replace conventional methods of diagnosis such as colonoscopy and endoscopy. Capsule endoscopy has cropped up as an effective method to perform endoscopy which is non-invasive and causes very little discomfort. Increasing consumer preference for minimally invasive medical procedures is likely to induce greater demand within the smart pills market.

Application of smart pills in monitoring pH, temperature, pressure, and drug adherence are further expected to catapult the growth of the market. Considerable research in the field of smart pills purveyed by heavy investments is also favoring the growth of the market. Other factors fostering market growth include conducive reimbursement landscape and increasing geriatric population. On the other hand, the market growth is restricted by factors such as regulatory restrictions and high costs of smart pills.

Competitive Landscape

Global smart pills market players are CapsoVision, Inc., Proteus Digital Health, Inc., JINSHAN Science & Technology, MEDTRONIC, Check-Cap, BDD Limited, Olympus Corporation, PENTAX Medical, FUJIFILM Holdings Corporation, MEDISAFE, INTROMEDIC, and RF Co., Ltd. are the notable players in the global smart pills market.

Segmentation

The global smart pills market has been segmented based on application, target area, disease indication, and end user.

 

By application, the smart pills market has been segmented into capsule endoscopy, drug delivery, patient monitoring, and others. The capsule endoscopy segment has been further segmented into small bowel capsule endoscopy, controllable capsule endoscopy, colon capsule endoscopy, and others. The patient monitoring segment has been further segmented into capsule pH monitoring and others.

By target area, the smart pills market has been segmented into esophagus, small intestine, large intestine, and stomach.

By disease indication, the smart pills market has been segmented into esophageal diseases, small bowel disases, colon diseases, and others.

By end user, the smart pills market has been segmented into hospitals, diagnostic center, and research institute.

Regional Analysis

By region, the smart pills market outlook has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

Conducive reimbursement scenario, the surging prevalence of chronic diseases, a nd fast uptake of advanced technology are the factors supporting the growth of the market in the region. The Americas account for the foremost share of the smart pills market.

Europe follows the Americas closely and accounts for the second most significant share of the smart pills market. Robust healthcare infrastructure, the high incidence rate of lifestyle-related diseases such as obesity, gastroesophageal reflux disease (GERD), and gastric ulcers have generated high demand for smart pills in the region. Moreover, European countries invest heavily in healthcare which acts as a plus for the growth of the market.

The APAC market is poised to perform relatively well and emerge as the fastest-growing market for smart pills. Percolation of advanced healthcare technologies in the region coupled with high healthcare expenditure in the developing countries of the region favors the growth of the market. Besides, increase in geriatric population and prevalence of various chronic diseases contribute to the growth of the market.

The minimum share of the smart pills market is held by MEA. Lack of knowledge, low healthcare penetration, and poor economic conditions, especially in the African region is hindering the growth of the market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

 

Poultry Vaccines Market Outlook Overview, Trends,Share and Forecast by 2032

Market Highlights

The Poultry Vaccines Market Share was worth USD 1.8 billion in 2022 and is expected to reach USD 3.32 billion by 2032 at 7.05% CAGR during the forecast period 2023 to 2032.

The high cost associated with poultry vaccines, lack of awareness regarding poultry vaccines, and unaffordability of veterinary services in underdeveloped and developing regions may hamper the growth of the Poultry Vaccines Market Share during the assessment period. For instance, according to the National Institute of Standards and Technology (NIST), in January 2016, more than 35.0% of vaccines lost their potency during the global shipping, as they were stored at temperatures that were either too high or too low.

Segmentation

The global Poultry Vaccines Market Outlook has been segmented based on diseases, technology, dosage form and region.

·       Based on disease, the market has been classified as infectious bronchitis, avian influenza, marek's disease, newcastle disease, and others. the market, by technology, has been segmented into toxoid vaccines, recombinant vaccines, inactivated vaccines, live attenuated vaccines (lav), and others. based on dosage form, the market has been segmented into duct vaccines, liquid vaccines, and freeze-dried vaccines.

·       Based on technology, live attenuated vaccines segment is expected to hold the largest market share of the poultry vaccines market during the forecast period. Also, recombinant vaccines segment to register the fastest growth in the global poultry vaccines market during the forecast period.

Key Players

Some of the key Poultry Vaccines Market Players are

Boehringer Ingelheim,

Elanco,

MSD & Co.,

Zoetis Inc,

Ceva Animal Health Inc.,

Phibro Animal Health Corporation,

Virbac,

Hipra,

Venkys,

Biovet, and

Anicon GmbH, and

Others.

Regional Analysis

The Poultry Vaccines Market Outlook is likely to dominate by Americas during the forecast period owing to the awareness about the prevention of animal-to-human transmission diseases, rising demand for safe animal food supply, and increasing investment in research and development for animal vaccines. Moreover, high expenditure spending and favorable reimbursement policy also fueling the growth of the market during forecast periods. The European market is expected to be the second-largest due to government support for research & development and improved animal husbandry practices. However, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to rising awareness and increase in the number of animal welfare programs. The market in the Middle East & Africa is likely to account for the smallest share of the global poultry vaccines market.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

 

Biologic Therapy Market Players, Industry Trends & Forecast by 2030

Global Biologic Therapy Market to Grow Healthily over 2023

Biologic therapy is gaining traction. According to a report published by Market Research Future (MRFR), the global biologic therapy market size is set to reach USD 288.03 billion by 2030 at a CAGR 8.20% over the forecast years 2023-2030. Biologic therapy is viewed as an innovative treatment module based on products sourced from living organisms.

Biologic therapy is used to stimulate or suppress the immune system for treatment purposes. The therapy finds application in treatment of diseases such as infection, cancer and several other diseases. Advances in the field of biologic therapeutic is boosting the application scope of biologic therapy. Rising demand for biological and targeted drug therapies is making a positive impact on the global biological therapy market. The R&D pipeline for biologic therapy is expected to grow in the future as pharmaceutical companies realise the vast market opportunities. 

Global Biologic Therapy Market: Competition Analysis

Global biologic therapy market players include

         ·         Bristol-Myers Squibb,

         ·         Amgen Inc.,

         ·         Eli Lilly,

         ·         Seattle Genetics, Inc.,

         ·         GlaxoSmithKline Plc.,

         ·         Novartis International AG,

         ·         Celgene Corporation and

         ·         Spectrum Pharmaceuticals, Inc.

Global Biologic Therapy Market: Segmental Analysis

MRFR’s report includes a detailed segmental analysis of the market based on therapy, product type, end-user and application. Based on therapy, the market has been segmented into vaccines therapy, cell therapy, protein therapy and others. Based on product type, the market has been segmented into services, instruments and kit and reagents. Based on end-user, the market has been segmented into hospitals and clinic, research centers and speciality centers. Based on application, the market has been segmented into blood and blood-related products testing, tissue and tissue-related products testing, vaccine and therapeutics development, stem cell research and cellular and gene therapy.

Global Biologic Therapy Market: Regional Analysis

On the basis of region, the biologic therapy market insights has been segmented into North America, Europe, the Middle East & Africa (MEA), Latin America and Asia Pacific (APAC). North America represents an important market for biologic therapy. Rising geriatric population, growing cancer prevalence in countries such as the U.S. and Canada are some of the factors supporting the market growth in the region. Data released by United States Census Bureau reveals that the total count of Americans aged 65 and above surpassed 49.2 Mn in 2016. Advanced countries in North America have robust health coverage policies along with a quicker access to latest biologic therapeutics. Many market players operating in North America are focusing on patient-centric products. In addition, companies are focusing on delivering customized therapeutics. High healthcare spending in the region is also influencing the market growth. The Center for Disease Control and Prevention reported that healthcare expenditure in the U.S reach to 3.2 trillion in 2015.

Europe in hold the second spot in the global biologic therapy market in terms of revenue. The market in Europe is expected to exhibit a healthy growth over the next couple of years. The healthcare sector remains focused on innovation and continue to excel in delivering quality care. In addition, presence of an advanced healthcare system is reflecting favourably on the market in the region. Many of the advanced countries in Europe have large pool of geriatric population. Data released by Eurostat revealed that more that 19% of the over population in Europe is aged 65 and above.

Asia Pacific is emerging as a highly attractive market for biologic therapy. It is projected that the market in APAC will demonstrate the fastest growth during the forecast period. Increased occurrence of lifestyle diseases is driving the demand for biologic therapy. Rising healthcare expenditure, increased awareness level and improving healthcare infrastructure are some of the key factors influencing the market in APAC.

The market in MEA is expected to witness a relatively slower growth during the forecast period. This is mainly owing low penetration and limited access. However, increased efforts towards improving healthcare standard in GCC countries is likely to create market opportunities.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America

Pharmaceutical Sterility Testing Market Players, Outlook, Trends & Size by 2032

Market Highlights

According to MRFR analysis, the global Pharmaceutical Sterility Testing Market size is expected to register a CAGR of 6.10% from 2023 to 2032. Sterility can be defined as the non-appearance of viable microorganisms, dust, fibers, foreign particles, and other biological agents. Pharmaceutical sterility testing is performed on a wide range of biological medicinal products, including blood products, vaccines, biotechnology products, cell products, and tissue products, in accordance with WHO sterility requirements. Sterility testing is carried out by companies such as pharmaceutical companies, biotechnology companies, and medical device manufacturers to assess process control, raw material quality, and product validity.

The industry players focus on technological developments to dominate the global Pharmaceutical Sterility Testing Market. In addition, the key players are involved in new product launches, acquisitions, and joint ventures to augment their market positions. For instance, in July 2020, Neogen Corporation (US) has launched Soleris, an advanced test system that can rapidly detect a wide variety of microorganisms in a fraction of the time.

Key Players

Some of the Pharmaceutical Sterility Testing Market Players are.

§  Merck KGaA (Germany),

§  Rapid Micro Biosystems (US),

§  Sartorius AG (Germany),

§  Solvias AG (Switzerland),

§  SGS SA (Switzerland),

§  Boston Analytical (US),

§  bioMérieux, Inc. (France),

§  Charles River Laboratories International, Inc. (US),

§  Thermo Fisher Scientific, Inc. (US),

§  Pace Analytical Services, LLC (US),

§  Toxikon, Inc. (US),

§  Sotera Health (US),

§  Pacific Biolabs Inc. (US),

§  STRERIS Corporation (US),

§  WuXi AppTec (China).

Regional Analysis

North America is anticipated to dominate the global pharmaceutical sterility testing market, owing to the presence of several key players in the region and the rise in R&D investments by public and private players in the healthcare sector. Moreover, the increase in the number of pipeline products and the launch of advanced drugs based on the biopharmaceutical that requires unique pharmaceutical sterility testing processes are also propelling the market growth.

The European pharmaceutical sterility testing market has been categorized into Germany, France, the UK, Italy, Spain, and the rest of Europe. Increasing government initiatives and extensive availability of research grants in the European countries are expected to propel the growth of the pharmaceutical sterility testing market in the region. Furthermore, the presence of outsourcing companies for pharmaceutical sterility testing is also supporting the growth of the pharmaceutical sterility testing market.

Asia-Pacific is anticipated to be the fastest-growing regional market over the forecast period due to the increasing harmonization of the regulatory standards with the International Council for Harmonisation (ICH) standards in developing nations, technological advances, and increasing investment in healthcare infrastructure. In addition, growing investment by governments from the China and India for offering cost-effective medications is providing lucrative opportunities for the growth of the pharmaceutical sterility testing market over the forecast period.

 In the Middle East, the UAE is the largest market due to the healthcare industry's development. Developing countries such as Argentina, Brazil, and Colombia, among others in Latin America, are also key contributors to the growth of the pharmaceutical sterility testing market insights.

Segmentation

The global sterility testing microbiology market has been segmented based on sample, product type, type, test type, and end user. By sample, the market has been segregated into sterile drugs, medical devices, and biologics. The sterile drugs segment is expected to witness high growth in 2020, Owing to the high adoption of several techniques adopted for product safety across the globe.

         ·         Based on product type, the global pharmaceutical sterility testing market has been classified into instruments, kits & reagents, and services. Kits & reagents held the largest segment share in 2020, owing to the repetitive purchase of these products by end users all around the world. In addition, cost efficiency and ease of use are related to the product.

         ·         Based on type, the global pharmaceutical sterility testing market has been classified into in-house and outsourcing.

         ·         Based on test type, the global pharmaceutical sterility testing market has been classified into sterility testing, bioburden testing, and bacterial endotoxin testing. The bacterial endotoxin testing segment held a major market share in 2020 due to the ongoing technological advancements in this segment.

·        Based on end user, the pharmaceutical sterility testing market is classified into compounding pharmacies, medical devices companies, pharmaceutical companies, and others. Pharmaceutical companies held the largest market share in 2020 due to the high growth of pharmaceutical and biological industries across the globe, and new drug approvals will boost the pharmaceutical sterility testing market during the forecasting period.

 

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Microbiome Sequencing Services Market Insights Growth During the Forecast Period

Market Highlights

It is estimated that the global Microbiome Sequencing Services Market Size is expected to register a CAGR ~ 18% during the forecast period of 2023–2032, with an estimated market value of USD 6.70 Billion in 2032.

Numerous factors such as high investment in next-generation sequencing, rising genome mapping programs in various countries, and the demand for microbiome research is anticipated to fuel the growth of the Microbiome Sequencing Services Market. Moreover, the increasing investments in next-generation sequencing by various public and private organizations have created a lucrative option for many companies to invest in providing microbiome sequencing services, leading to the overall growth of the market. For instance, according to the data published by the Wall Street Journal in 2016, reported that venture funding in microbiome firms raised by 458.5% to USD 114.5 million from 2022 to 2030.

Key Players

The global microbiome sequencing services market players are

Metabiomics Corp.,

Baseclear B.V.,

Clinical Microbiomics A/S,

EPIBIOME,

Merieux Nutrisciences Corporation,

Microbiome Insights Inc.,

Microbiome Therapeutics, LLC.,

MR DNA,

Rancho Biosciences,

Second Genome,

Ubiome, Inc., and

Zymo Research Corp.

Segmentation

The global microbiome sequencing services market insightts has been segmented into technology, application, and end user.

·        The market, based on technology, has been segmented into Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), short gun sequencing, targeted gene sequencing, RNA sequencing, and others.

·        The market, by application, has been further segmented into gastrointestinal diseases, infectious diseases, CNS diseases, oncology, and others.

·        The market, by end user, has been segmented into research and academic institutes, pharmaceutical and biotechnology companies, and others.

Regional Analysis

The market in the Americas is expected to dominate the global microbiome sequencing services market during the forecast period owing to the increasing per capita healthcare expenditure, and the heavy adoption of new technology in the region. Europe is expected to hold the second largest position in the global microbiome sequencing services market. The market growth in this region is because of the presence of a well-established healthcare system and increase in life-threatening diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the microbiome sequencing services market. Asia-Pacific is estimated to be the fastest growing region in the market due to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. The market in the Middle East & Africa is likely to account for the smallest share of the global microbiome sequencing services market. The market growth in this region owes to the low disposable income in the region.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America